ARIA ARIAD Pharmaceuticals, Inc.

23.99
+0  (0%)
Previous Close 23.99
Open 0.00
Price To book 0.00
Market Cap 4.66B
Shares 194,200,000
Volume 0
Short Ratio 1.22
Av. Daily Volume 9,913,520

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

To be acquired by Takeda. Deal to close by the end of February 2017.
To be acquired

Latest News

  1. ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o
  2. Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.
  3. ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib
  4. ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  5. Why Ariad Pharmaceuticals Stock Nearly Doubled in January
  6. Ariad Submits Marketing Application to EU Agency
  7. ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency
  8. Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan
  9. Takeda Reports Q3 FY2016 Results and Improves Year-End Outlook
  10. Ariad mum on layoffs in letter to employees: ‘It’s business as usual’
  11. Ariad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC
  12. Ariad played hardball to boost Takeda buyout price, federal filings show
  13. Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017
  14. Can The Uptrend Continue for ARIAD Pharmaceuticals (ARIA)?
  15. Takeda Commences Cash Tender Offer for All Outstanding Shares of ARIAD Pharmaceuticals, Inc.
  16. 5 Expensive Drugs That Could End Up in Trump's Crosshairs
  17. Ariad Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of ARIA Shareholders
  18. Jazz Begins Phase III Study for Label Expansion of Defitelio
  19. Becton, Dickinson Commercially Launches Precise WTA Kits
  20. These 3 Stocks Have Doubled Since Election Day